Alterity Therapeutics Limited Stock Short Ratio
| PRNAF Stock | USD 0 0.00 0.00% |
Fundamental analysis of Alterity Therapeutics allows traders to better anticipate movements in Alterity Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Alterity |
Alterity Therapeutics Limited Company Short Ratio Analysis
Alterity Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Alterity Therapeutics Limited has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The short ratio for all United States stocks is 100.0% higher than that of the company.
Alterity Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterity Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics of similar companies.Alterity Therapeutics is currently under evaluation in short ratio category among its peers.
Alterity Fundamentals
| Return On Equity | -0.39 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.51) % | |||
| Operating Margin | (3.03) % | |||
| Current Valuation | (7.2 M) | |||
| Shares Outstanding | 2.41 B | |||
| Shares Owned By Insiders | 15.14 % | |||
| Shares Owned By Institutions | 0.33 % | |||
| Price To Earning | 0.88 X | |||
| Price To Book | 0.67 X | |||
| Price To Sales | 3.12 X | |||
| Gross Profit | 4.76 M | |||
| EBITDA | (15.08 M) | |||
| Net Income | (12.85 M) | |||
| Cash And Equivalents | 34.81 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 117.49 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 7.07 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (12.34 M) | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.87 | |||
| Market Capitalization | 18.77 M | |||
| Total Asset | 41.36 M | |||
| Retained Earnings | (125 M) | |||
| Working Capital | 32 M | |||
| Current Asset | 34 M | |||
| Current Liabilities | 2 M | |||
| Z Score | 91.2 | |||
| Net Asset | 41.36 M |
About Alterity Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterity Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in Alterity Pink Sheet
Alterity Therapeutics financial ratios help investors to determine whether Alterity Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterity with respect to the benefits of owning Alterity Therapeutics security.